Keeping the Weight Off After Semaglutide: What the Evidence Shows

The trial data on weight regain: what the STEP 1 extension found

The STEP 1 trial, published in the New England Journal of Medicine, followed adults with obesity who had lost an average of around 15% of body weight on semaglutide 2.4mg over 68 weeks. A published extension then tracked what happened after treatment stopped. Within a year of stopping, participants had regained about two-thirds of what they had lost. Body weight, waist circumference and cardiometabolic markers all moved back toward baseline.

This is not a failure of willpower. Semaglutide works partly by reducing appetite signals from gut hormones; when the medicine clears, those signals return to their pre-treatment level. The body's defended weight set-point reasserts itself, a mechanism well-recognised in obesity medicine. Understanding this upfront is the most useful thing a patient can do, because it shapes whether you treat the end of treatment as a cliff edge or a transition.

The evidence does not mean that keeping weight off after semaglutide is impossible. It means that stopping without a plan makes regain very likely. It also tells us that the structural habits formed during treatment are the variable that matters most once the medicine is gone. If you have questions about how long semaglutide can be used, the answer varies considerably by individual clinical circumstance.

Building habits during treatment that carry weight after it ends

The window when semaglutide is reducing appetite is the practical time to establish eating and activity patterns that do not depend on the medicine to persist. That sounds obvious; fewer people act on it than you might expect. A question our prescribers hear regularly is whether the weight will just come back regardless, and the answer is that it is more likely to if treatment is treated as a passive experience rather than an active one.

Protein adequacy is the single dietary factor with the strongest maintenance evidence. Higher protein intake supports lean muscle mass, and lean mass sets the floor for resting energy expenditure. On a reduced-calorie intake it is easy to undereat protein; tracking it briefly, even mid-treatment, helps calibrate. Fibre from vegetables, legumes and wholegrains slows gastric emptying and sustains satiety independently of the medicine. These two levers together make the dietary transition off semaglutide substantially smoother.

Resistance exercise matters more than cardiovascular exercise for weight maintenance specifically, because it preserves muscle. The NHS healthy weight guidance recommends strength activity at least twice weekly. Starting this during treatment, when appetite is suppressed and adherence is easier, is more effective than trying to begin it after stopping.

Sleep and stress management sit in the same category: hard to prioritise, meaningfully impactful. Chronic sleep restriction raises ghrelin and lowers leptin, which recreates part of the hormonal picture that made weight management difficult before treatment. Addressing it is not peripheral.

Options when stopping feels premature: longer treatment, dose reduction and transition

NICE's guidance on semaglutide (TA875) notes that the medicine is recommended for use within specialist weight management services and specifically flags that continuing may not be appropriate if less than 5% weight loss has occurred after six months on the maintenance dose. It does not, however, set a hard upper limit on duration for every patient; clinical context governs. Some people continue semaglutide long-term under ongoing review. Others move to a lower maintenance dose once their target weight range is stable, using less medicine to sustain the effect with fewer side effects. Others switch to tirzepatide, which acts on an additional gut-hormone receptor and may suit different metabolic profiles, the weight-loss treatment options page outlines what is licensed in the UK.

A planned, gradual reduction in dose almost always beats abrupt stopping. It gives the body time to adjust, gives the patient time to stress-test their habits, and allows the prescriber to observe what happens before the medicine is fully withdrawn. If you are thinking about whether weight loss is maintainable after stopping Wegovy, a frank conversation with your prescriber about the pacing of any reduction is the right first step, not a unilateral decision.

People who stop semaglutide and then regain weight are not unusual, and they are not disqualified from restarting. Prescribers assess each request on its clinical merits. The stigma around needing ongoing medication for a chronic condition belongs to a different era of thinking about obesity.

Practical signals that you may be ready to reduce or stop

No two patients leave treatment at the same point. The markers that tend to indicate a more stable transition are: sustained weight at goal for at least three to six months; established dietary patterns that do not feel effortful; an activity routine that happens without relying on motivation; and, ideally, resolution or reduction of the weight-related condition that originally qualified you. Prescribers will typically review all of these before recommending a reduction plan.

It is also worth knowing what to expect physically in the weeks after stopping. Appetite typically increases within days; this is normal and does not mean something has gone wrong. Understanding this in advance reduces the likelihood of interpreting normal hunger as failure. The timeline of changes after stopping Wegovy covers this in more detail. Some people find the transition more manageable than they expected; others find it harder. Neither is a verdict on their character.

The cost of ongoing private treatment is a real factor for many people. For context on how semaglutide is priced privately in the UK, the Wegovy cost page sets out what is typically included in a legitimate private prescription. What constitutes long-term value is a personal calculation, and it is one worth doing with your eyes open rather than discovering mid-treatment. The long-term weight maintenance guide covers the practical side in more depth alongside the clinical detail here.